- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Implant system maker Spinal Elements files for $100M Nasdaq IPO | ||
| Fr | Galecto bags $64M to push lung fibrosis med toward EU nod | ||
| Fr | United Airlines to offer COVID-19 testing, starting from SFO to Hawaii | ||
| Fr | Palladio bags $20M to take once-discarded drug through phase 3 | ||
| Fr | New atlas of the human heart could guide personalized medicine in cardiology | ||
| Fr | Novavax kick-starts phase 3 of COVID-19 vaccine in U.K. as cases surge across the country | ||
| Fr | Flagship's Valo emerges with $100M and plans to transform R&D | ||
| Fr | Chutes & Ladders-Day One brings on Gilead alum Bender as CEO | ||
| Fr | Looking for an edge in the wet AMD market, phase 3 biotech Opthea guns for $150M IPO | ||
| Do | Babson Diagnostics nets new CEO, plus $13.7M for its blood test devices | ||
| Do | Novo Nordisk tees up phase 3 trial for once-weekly insulin | ||
| Do | FDA greenlights its first coronavirus antibody blood test for the point of care | ||
| Do | Lumen bags U.S. grant for GI-focused COVID-19 antibody cocktail | ||
| Do | Poxel posts phase 3 diabetes data ahead of approval decision | ||
| Do | Agios helps identify genes that allow cancer to escape the immune system | ||
| Do | Moderna's COVID-19 vaccine investigator leaves FDA advisory committee over conflict of interest | ||
| Do | CTI Clinical Trial snaps up Clinart to boost its Middle East, North Africa reach | ||
| Do | Versant's Monte Rosa reels in $96M to bankroll 'molecular glue' treatments for cancer, other diseases | ||
| Mi | LabCorp to roll out Resolution Bio's lung cancer liquid biopsy test | ||
| Mi | Silverback Therapeutics nets $85M top-up to push lead ADC through phase 1 | ||
| Mi | Cognoa's AI-powered diagnostic app for autism clears clinical study, heads for FDA review | ||
| Mi | FDA to set high bar for emergency COVID-19 vaccine approvals | ||
| Mi | Roche, AC Immune's tau-blocking drug flops in Alzheimer's as biotech's shares halved | ||
| Mi | J&J starts COVID-19 vaccine phase 3, eyes early 2021 approval | ||
| Mi | New insights into the coronavirus spike protein could inspire vaccine development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
